Egypt Depression Therapeutics Market Report 2022 to 2030

Egypt Depression Therapeutics Market Analysis

$ 3999

The Egypt depression therapeutics market is expected to witness growth from $28 Mn in 2022 to $48 Mn in 2030 with a CAGR of 6.7% for the forecasted year 2022-2030. The growing incidence of depression in Egypt and its improving health infrastructure has resulted in the growth of the market. The Egypt depression therapeutics market is segmented by drug type, therapies, indication, and by end users. FPi Future Pharmaceutical, Quadri Pharma, and GlaxoSmithKline are the major players in the Egypt depression therapeutics market.

ID: IN10EGPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Parul Choudhary

Buy Now

Egypt Depression Therapeutics Market Executive Analysis

The Egypt depression therapeutics market size is at around $28 Mn in 2022 and is projected to reach $48 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period. The new general budget draft of Egypt includes $11.5 Bn in allocations for funding social protection, according to Finance Minister Mohamed Maait. Along with $600 Mn for the provision of medicines and medical apparatus, he added that $350 Mn had been set aside for health insurance and the state-funded treatment of the poor. The overall allocations for health reached $10 Bn, he said, adding that $15.3 Bn had been spent on college and pre-university education and that $2.5 Bn had been set aside for scientific research despite the difficulties and pressures on the state budget.

About 31% of Egyptians enduring mental health conditions are "suffering from depression that is related to substance abuse. The public health issue of major depressive disorder (MDD) is significant. By 2030, it is anticipated to be the leading source of disease burden globally. In Egypt, the frequency of depression varies from 23.7 to 74.5%.

Treatment Resistant Depression (TRD) is defined as sadness that is unresponsive to antidepressant medication therapy when given in a sufficient dosage for a sufficient period. Several psycho-pharmacotherapeutic approaches have been proposed to treat TRD, with augmentation therapy presently being the first option advised if the initial antidepressant treatment does not produce the desired results. According to the best-known international research, lithium or second-generation antipsychotics should be used. Patients with depression or TRD frequently experience sleep disturbances; therefore, a sleep aid can be used to overcome this symptom. In contrast to the hypnotic agent zolpidem, which does not affect residual daytime sedation or psycho-motor impairment, high doses of benzodiazepines often result in residual daytime sleepiness or "hangover" and cause cognitive impairment and respiratory depression.

Egypt Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

A mounting concern in Egypt is depression, which affects 4–10% of the country's population. As a result, there is a growing need for depression treatments. The acceptance and directness toward depression have increased in Egypt over the previous years as a result of the country's cumulative awareness of mental health issues. This has made it more probable that people will seek treatment by lowering the stigma attached to the disorder. In recent years, Egypt has made substantial investments in its healthcare system, including mental health services. As a result, more people nationwide now have better access to depression treatment opportunities. This has resulted in the development of the Egypt depression therapeutics market.

Market Restraints

An increase in the incidence of drug withdrawals, a surge in the number of generic medicines, the incidence of drug-resistant mental health conditions such as Treatment Resistant Depression (TRD), and an ineffective pipeline are some of the aspects that could have an undesirable impact on the Egypt depression therapeutics market's development.

Competitive Landscape

Key Players

Chemipharm (EGY)
DBK Pharma (EGY)
Copad Pharma (EGY)
FPi Future Pharmaceutical (EGY)
Quadri Pharma (EGY)
GlaxoSmithKline
Elly Lilly
Allergan
Takeda Pharmaceutical
Intellipharmaceutics
Otsuka Holdings
H.Lundbeck

Healthcare Policies and Regulatory Landscape

The residents of Egypt have access to a public healthcare system that offers them vital medical care and treatment. Public hospitals and clinics offer mental health treatments, such as depression treatment. However, based on the area and the particular facility, both the value and convenience of these services may vary. Depending on the category of therapy and the healthcare provider, different depression therapeutics are compensated under different situations in Egypt. In most cases, patients are required to pay for their care upfront before submitting a claim to their insurance company for reimbursement. For patients, the procedure can be made simpler by some providers who give direct billing to insurance firms. To enhance the nation's mental health facilities, the Egyptian government has started several initiatives. For example, in an effort to augment mental health services and decrease the stigma surrounding mental health diseases, the National Mental Health Strategy was introduced in 2018. The insurance coverage may change as a result of these initiatives.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.